Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
52 hedge funds and large institutions have $2.79M invested in Navidea Biopharmaceuticals Inc. in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 6 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
0% less capital invested
Capital invested by funds: $2.79M → $2.79M (-$8K)
4% less funds holding
Funds holding: 54 → 52 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$12.8K |
| 2 |
CWM
Cabot Wealth Management
Salem,
Massachusetts
|
+$11.7K |
| 3 |
Jane Street
New York
|
+$8.85K |
| 4 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
+$5.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$81K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$9.14K |
| 3 |
PP
PDS Planning
Dublin,
Ohio
|
-$8K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$3K |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.17K |
NAVB Hedge Fund Activity: Q3 2018 in Review
52 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2018, worth a combined $2.79M — down 0.29% from $2.79M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NAVB and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Virtu Financial, adding an estimated $12.8K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $81K sold.
- 52 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2018, down from 54 in Q2 2018.
- Funds reported $2.79M of Navidea Biopharmaceuticals Inc. stock for Q3 2018, down 0.29% quarter-over-quarter.
- 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2018 and 6 closed out, a net change of -2 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2018 was Virtu Financial, an estimated $12.8K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2018 was Jacobs Levy Equity Management, an estimated $81K sold.
Based on aggregated 13F filings for Q3 2018.